Extracellular rage binding protein (EN-RAGE) and uses thereof

Details Extracellular rage binding protein (EN-RAGE) and uses thereof Extracellular rage binding protein (EN-RAGE) and uses thereof

2006-07-25

2006-07-25

Murphy, Joseph (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S141100, C424S142100, C424S143100, C514S002600, C514S012200

Reexamination Certificate

active

07081241

ABSTRACT:
The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a)(i) and the peptide of step (a)(ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

REFERENCES:
patent: 5864018 (1999-01-01), Morser et al.
patent: 0731166 (1996-09-01), None
patent: WO9739121 (1997-10-01), None
patent: WO9739125 (1997-10-01), None
Hori et al, Journal of Biological Chemistry, vol. 27, No. 43, pp. 25752-25761, Oct. 1995.
Ritthaler et al, American Journal of Pathology, vol. 146, No. 3, pp. 688-694, Oct. 1995.
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc. 126-128 and 228-234.
Mickle JE et al. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am. May 2000;84(3):597-607.
Yan et al., Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 290: 523-527, 2000.
Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes.Diabetes40: 405-412 (Exhibit 2).
Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presenilin 1 variants elevate Aβ1-42/1-40 rationin vitroandin vivo. Neuron17: 1005-1013 (Exhibit 3).
Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for a advanced glycation end products in tissues.Am. J. Pathol.143(6): 1699-1712 (Exhibit 4).
Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications.Diabetes Care15(12): 1835-1842 (Exhibit 5).
Cai, X-D., et al. (1993). Release of excess amyloid β protein from a mutant amyloid β protein precursor.Science259: 514-516 (Exhibit 6).
Citron, M., et al. (1997). Mutant presenilins of Alzheimer's Disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice.Nature Medicine3(1): 67-72 (Exhibit 7).
Dell'Angelica, E. C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes.J. Biol. Chem.269: 28929-28936 (Exhibit 8).
Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing.J. Surg. Res.50: 308-313 (Exhibit 9).
Fu, M-X., et al. (1996). The advanced glycation end product, N∈-(carboxymethly) lysine, is a product of both lipid peroxidation and glycoxidation reactions.J. Biol. Chem.271: 9982-9986.
Giardino, I., et al. (1994). Nonenzymatic glycosylationin vitroand in bovine endothelial cells alters basic fibroblast growth factor activity.J. Clin. Invest.94: 110-117 (Exhibit 11).
Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases.Science272: 689-693. (Exhibit 12).
Khoury, J. E., et al. (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors.J. Biol. Chem.269: 10197-10200 (Exhibit 13).
Kuo, Y-M., et al. (1996). Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer Disease brains.J. Biol. Chem.271(8): 4077-4081 (Exhibit 14).
Lander, H. M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21rasdependent mitogen-activated protein kinase pathway regulated by oxidant stress.J. Biol. Chem.272: 17810-17814 (Exhibit 15).
Ledesma, M. D., et al. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments.J. Biol. Chem.269(34): 21614-21619 (Exhibit 16).
Li, J. and A. M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.J. Biol. Chem.272: 16498-16506 (Exhibit 17).
Lorenzo, A. and B. A. Yanker (1994). β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red.Proc. Nat. Acad. Sci. USA91: 12243-12247 (Exhibit 18).
Mattson, M. P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium.Brain Res.676: 219-224 (Exhibit 19).
Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-β2 Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway.J. Clin. Invest.98: 1088-1094 (Exhibit 20).
Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus.Am. J. Pathol.143(6): 1649-1656 (Exhibit 21).
Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.J. Biol. Chem.267: 14998-15004 (Exhibit 22).
Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.Arterioscl. Thromb. and Vasc. Biol.15(5): 571-582 (Exhibit 23).
Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.Nature Medicine4: 1025-1031 (Exhibit 24).
Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts.Circulation Supplement.Abstract 3079 (Exhibit 25).
Reddy, S., et al. (1995). N∈-(Carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.Biochemistry34: 10872-10878 (Exhibit 26).
Renard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharm. 52: 54-62 (Exhibit 27).
Roher, A. E., et al. (1996). Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease.J. Biol. Chem.271(34): 20631-20635 (Exhibit 28).
Schleicher, E. D., et al. (1997). Increased accumulation of the glycoxidation product N∈-(carboxymethyl) lysine in human tissues in diabetes and aging.J. Clin. Invest.99: 457-468 (Exhibit 29).
Schmidt, A. M., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice.J. Clin Invest.96: 1395-1403 (Exhibit 30).
Schmidt, A. M., et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins.Proc. Nat'l Acad. Sci. USA91: 8807-8811 (Exhibit 31).
Schmidt, A. M., et al. (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface.J. Biol. Chem.267: 14987-14997 (Exhibit 32).
Schmidt, A. M., et al. (1994). Cellular receptors for advanced glycation end products.Arterioscler. Thromb.14: 1521-1528 (Exhibit 33).
Schmidt, A. M., et al. (1995). The dark side of glucose. (News and Views).Nature Medicine1: 1002-1004 (Exhibit 34).
Schmidt, A. M., et al. (1993). Regulation of h

Affiliated with

Also associated with

Rating

Extracellular rage binding protein (EN-RAGE) and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Extracellular rage binding protein (EN-RAGE) and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extracellular rage binding protein (EN-RAGE) and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3550137